Trial Profile

Development of an Algorithm for Identification of Responders to Short Term Treatment With Esomeprazole (Nexium) in Primary Care.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esomeprazole (Primary)
Indications Dyspepsia; Gastro-oesophageal reflux
Focus Therapeutic Use
Acronyms RESPONSE
Sponsors AstraZeneca

Most Recent Events

27 Oct 2009 Secondary endpoint results presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
03 Feb 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com